COMPLETED

Multisite Virtual Reality Intervention for Speech Anxiety

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.

Official Title

Multisite Virtual Reality Intervention for Speech Anxiety

Quick Facts

Study Start:2024-10-08
Study Completion:2025-07-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06593847

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Self-report of 18 - 70 years of age
  2. * Current student at a participating University
  3. * Ability to read English to provide informed consent
  4. * Familiarity with a computer keyboard and mouse or a touch screen device (e.g. phone, tablet).
  5. * For Phase 2: speech anxiety scale score of ≥ 18 on the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS)
  1. * Previous participation (i.e., no participant may take the survey more than once).

Contacts and Locations

Principal Investigator

Michael Otto, PhD
PRINCIPAL_INVESTIGATOR
Boston University

Study Locations (Sites)

University of Arizona
Tucson, Arizona, 85721
United States
Southern Illinois University
Carbondale, Illinois, 62901
United States
Tufts University
Boston, Massachusetts, 02155
United States
Boston University
Boston, Massachusetts, 02215
United States
Albright College
Reading, Pennsylvania, 19604
United States
University of Texas at Austin
Austin, Texas, 78712
United States

Collaborators and Investigators

Sponsor: Boston University Charles River Campus

  • Michael Otto, PhD, PRINCIPAL_INVESTIGATOR, Boston University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-08
Study Completion Date2025-07-23

Study Record Updates

Study Start Date2024-10-08
Study Completion Date2025-07-23

Terms related to this study

Additional Relevant MeSH Terms

  • Public Speaking
  • Speech Anxiety